ProMIS Neurosciences Announces Board and Officer Changes
Ticker: PMN · Form: 8-K · Filed: 2025-10-24T00:00:00.000Z
Sentiment: neutral
Topics: leadership-change, governance, officer-appointment
TL;DR
ProMIS Neurosciences shakes up its board and exec team.
AI Summary
ProMIS Neurosciences Inc. announced on October 22, 2025, a change in its board of directors, including the election of new directors and the appointment of certain officers. The company also disclosed compensatory arrangements for these officers. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
Changes in a company's board and executive officers can signal shifts in strategy, governance, or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and officer compensation can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- ProMIS Neurosciences Inc. (company) — Registrant
- October 22, 2025 (date) — Date of earliest event reported
- Securities Exchange Act of 1934 (legal_document) — Governing regulation
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors and departure of certain officers, but specific names and details of the changes are not provided in this excerpt.
Were there any new officer appointments?
Yes, the filing mentions the appointment of certain officers.
What is the purpose of this 8-K filing?
This 8-K filing serves as a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting significant corporate events.
When was the earliest event reported in this filing?
The earliest event reported was on October 22, 2025.
What is the company's jurisdiction of incorporation?
The company is incorporated in Ontario, Canada.
Filing Stats: 990 words · 4 min read · ~3 pages · Grade level 10.2 · Accepted 2025-10-24 16:10:09
Key Financial Figures
- $40,000 — Alex will also receive an annual fee of $40,000 for service as a director. In addition,
Filing Documents
- pmn-20251022x8k.htm (8-K) — 39KB
- pmn-20251022xex99d1.htm (EX-99.1) — 21KB
- pmn-20251022xex99d1001.jpg (GRAPHIC) — 7KB
- 0001104659-25-102137.txt ( ) — 204KB
- pmn-20251022.xsd (EX-101.SCH) — 3KB
- pmn-20251022_def.xml (EX-101.DEF) — 3KB
- pmn-20251022_lab.xml (EX-101.LAB) — 18KB
- pmn-20251022_pre.xml (EX-101.PRE) — 12KB
- pmn-20251022x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 22, 2025, the Company issued a press release announcing Dr. Alex's appointment to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: October 24, 2025 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer